Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies

Since the approval of the first immune checkpoint inhibitor (ICI) 9 years ago, ICI-therapy have revolutionized cancer treatment. Lately, antibodies blocking the interaction of programmed cell death protein (PD-1) and ligand (PD-L1) are gaining momentum as a cancer treatment, with multiple agents and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Shirley, Sharma, Umesh C., Tuttle, Cheyanna, Pokharel, Saraswati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887301/
https://www.ncbi.nlm.nih.gov/pubmed/33614750
http://dx.doi.org/10.3389/fcvm.2021.619650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887301/
https://www.ncbi.nlm.nih.gov/pubmed/33614750
http://dx.doi.org/10.3389/fcvm.2021.619650

Ejemplares similares